Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge assisted Active Biotech in licensing deal regarding ANYARA
Mandate

Vinge assisted Active Biotech in licensing deal regarding ANYARA

October 27, 2016

Vinge has assisted Active Biotech AB (publ.) in entering into a development and licensing agreement with NeoTX Therapeutics Ltd (”NeoTX”) regarding Active Biotech’s investigational compound ANYARA. NeoTX will be responsible for the worldwide clinical development and commercialization of the drug for cancer indications.
 
Vinge’s team consisted of Erik Sjöman and Kristoffer Franzkeit.

Related

Vinge has advised Acrinova in connection with voluntary share redemption offering

 Vinge has advised Acrinova AB (publ) in connection with its voluntary share redemption offering. The offer comprised approximately one-third of the shares in Acrinova, and the acceptance rate reached approximately 97.34 percent, representing a redemption value of approximately SEK 367.4 million.
October 27, 2025

Vinge advises Revivo Group in conjunction with the acquisition of Lejon Entreprenad

 Revivo Group, a comprehensive provider of qualified surface treatment services, has acquired Lejon Entreprenad, a well-established specialist company offering qualified services within surface treatment, including industrial painting, anti-corrosion painting, and FROSIO inspections.
October 27, 2025

Vinge has advised Ingka Investments on its largest forestland acquisition

 Ingka Investments, the investment arm of Ingka Group (the world’s largest IKEA retailer), has agreed to acquire approximately 153,000 hectares of land, mainly forestland, from Södra, Sweden’s largest forest owners’ association.
October 20, 2025